Prostate-specific membrane antigen (PSMA) is overexpressed in most PC cells and levels correlate with disease progression, making it a favorable diagnostic and therapeutic target in mCRPC (2,6,7). The gene discussed is FOLH1; the disease is pachyonychia congenita.